Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines

Cell Growth and Differentiation

Volumn 7, Issue 12, 1996, Pages 1723-1732

  Pokrovskaja, Katja ^a   Ehlin Henriksson, Barbro ^a   Bartkova, Jirina ^b   Bartek, Jiri ^b   Scuderi, Richard ^c   Szekely, Laszlo ^a   Wiman, Klas G ^a   Klein, George ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; MESSENGER RNA; MITOGENIC AGENT; VIRUS ANTIGEN;

ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; BURKITT LYMPHOMA; CELL IMMORTALIZATION; CELL TRANSFORMATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; PHENOTYPE; PRIORITY JOURNAL;

B-LYMPHOCYTES; BLOTTING, NORTHERN; BLOTTING, WESTERN; BURKITT LYMPHOMA; CELL LINE; CYCLINS; FLOW CYTOMETRY; GENE EXPRESSION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; NERVE TISSUE PROTEINS; PHENOTYPE; RNA, MESSENGER; TUMOR VIRUS INFECTIONS;

HUMAN HERPESVIRUS 4;

EID: 0029831557     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Sherr, C. J. G1 phase progression: cyclin on cue. Cell, 79: 551-555, 1994.
2. Bates, S., Parry, D., Bonetta, L., Vousden, K., Dickson, C., and Peters, G. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene, 9: 1633-1640, 1894.
3. Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J., and Livingston, D. M. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell, 73: 487-497, 1993.
4. Dowdy, S. F., Hinds, P. W., Louie, K., Reed, S. I., Arnold, A., and Weinberg, R. Physical interaction of the retinoblastoma protein with human D cyclins. Cell, 73: 499-511, 1993.
5. Beijersbergen, R. L., Carlee, L., Kerkhoven, R. M., and Bernards, R. Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes. Genes Dev., 9: 1340-1353, 1995.
6. Sherr, C. J. Mammalian G1 cyclins. Cell, 73: 1059-1065, 1993.
7. Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J., Bar-Sagi, D., Roussel, M. F., and Sherr, C. J. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev., 7: 1559-1571, 1993.
8. Lukas, J., Bartkova, J., Welcker, M., Petersen, O. W., Peters, G., Strauss, M., and Bartek, J. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene, 10: 2125-2134, 1995.
9. Lukas, J., Pagano, M., Staskova, Z., Draetta, G., and Bartek, J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumor cells. Oncogene, 9: 707-718, 1994.
10. Baldin, V., Lukas, J., Markote, M. J., Pagano, M., and Draetta, G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev., 7: 812-821, 1993.
11. Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E., Tsujimoto, Y., Harris, N. L., and Arnold, A. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc. Natl. Acad. Sci. USA, 88: 9638-9642, 1991.
12. Bartkova, J., Lukas, J., Müller, H., Strauss, M., Gusterson, B., and Bartek, J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res., 55: 949-956, 1995.
13. Bartkova, J., Lukas, J., Strauss, M., and Bartek, J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene, 10: 775-778, 1995.
14. Bartkova, J., Lukas, J., Strauss, M., and Bartek, J. The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int. J. Cancer, 58: 568-573, 1994.
15. Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicolson, R. I., de Fasio, A., Watts, C. K. W., Musgrove, E. A., and Sutherland, R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8: 2127-2133, 1993.
16. Boer, C. J., Krieken, J., Kluin-Nelemans, H. C., Kluin, P. M., and Schuuring, E. Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene, 10: 1833-1840, 1995.
17. Motokura, T., and Arnold, A. Cyclin D and oncogenesis. Curr. Opin. Genet. Dev., 3: 5-10, 1993.
18. Ajchenbaum, F., Ando, K., DeCaprio, J. A., and Griffin, J. D. Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes. J. Biol. Chem., 268: 4113-4119, 1993.
19. Kato, J-Y., and Sherr, C. J. Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. Proc. Natl. Acad. Sci. USA, 90: 11513-11517, 1993.
20. Ando, K., Ajchenbaum-Cymbalista, F., and Griffin, J. D. Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc. Natl. Acad. Sci. USA, 90: 9571-9575, 1993.
21. Herber, B., Truss, M., Beato, M., and Muller, R. Inducible regulatory elements in the human cyclin D1 promoter [published erratum appears in Oncogens, 9: 2105-2107, 1994]. Oncogene, 9: 1295-1304, 1994.
22. Brooks, A. R., Shiffman, D., Chan, C. S., Brooks, E. E., and Milner, P. G. Functional analysis of the human Cyclin D2 and cyclin D3 promoters. J. Biol. Chem., 271: 9090-9099, 1996.
23. Tamaru, T., Okada, M., and Nakagawa, H. Differential expression of D type cyclins during neuronal maturation. Neurosci. Lett., 168: 229-232, 1994.
24. Horiguchi-Yamada, J., Yamada, H., Nakada, S., Ochi, K., and Nemoto, T. Changes of G1 cyclins, CDK2, and cyclin A during the differentiation of HL60 cells induced by TPA. Mol. Cell Biochem., 132: 31-37, 1994.
25. Kiess, M., Gill, R. M., and Hamel, P. A. Expression of the positive regulator of cell cycle progression, cyclin D3, is induced during differentiation of myoblasts into quiescent myotubes. Oncogene, 10: 159-166, 1995.
26. Gregory, C. D. Epstein-Barr virus and B cell survival. Med. Virol., 2: 205-220, 1992.
27. Gregory, C. D., Tursz, T., Edwards, C. F., Tetaud, C., Talbot, M., Caillou, B., Rickinson, A. B., and Lipinski, M. Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J. Immunol., 139: 313-318, 1987.
28. Rowe, M., Rowe, D. T., Gregory, D., Young, L. S., Farrell, P. J., Rupani, H., and Rickinson, A. B. Differences in B cell growth phenotype reflects novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J., 6: 2743-2751, 1987.
29. Palmero, I., Holder, A., Sinclair, A. J., Dickson, C., and Peters, G. Cyclins D1 and D2 are differentially expressed in human B-lymphoid cell lines. Oncogene, 8: 1049-1054, 1993.
30. Sinclair, A. J., Palmero, I., Peters, G., and Farrell, P. J. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalisation of resting human B lymphocytes by Epstein-Barr virus. EMBO J., 13: 3321-3328, 1994.
31. Kempkes, B., Spitkovsky, D., Jansen-Durr, P., Ellwart, J. W., Kremmer, E., Rottenberger, C., Bornkamm, G. W., and Hammerschmidt, W. B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J., 14: 88-96, 1995.
32. Hollyoake, M., Stuhler, A., Farrell, P., Gordon, J., and Sinclair, A. The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. Cancer Res., 55: 4784-4787, 1995.
33. Sinclair, A. J., Palmero, I., Holder, A., Peters, G., and Farrell, P. J. Expression of cyclin D2 in Epstein-Barr virus-positive Burkitt's lymphoma cell lines is related to methylation status of the gene. J. Virol., 69: 1292-1295, 1995.
34. Masucci, M. G., Contreras-Salazar, B., Ragnar, E., Falk, K., Minarovits, J., Ernberg, I., and Klein, G. 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt lymphoma line RAEL. J. Virol., 63: 3135-3141, 1989.
35. Wang, F., Gregory, C., Sample, C., Rowe, M., Liebowitz, D., Murray, R., Rickinson, A., and Kieff, E. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol., 64: 2309-2318, 1990.
36. Ehlin-Henriksson, B., and Klein, G. Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation. Int. J. Cancer., 33: 459-463, 1984.
37. Trivedi, P., Cuomo, L., De Campos-Lima, P. O., Imreh, M. P., Kvarnung, K., Klein, G., and Masucci, M. G. Integration of a short Epstein-Barr virus DNA fragment in a B95-8 virus converted Burkitt lymphoma line expressing Epstein-Barr nuclear antigens EBNA2 and EBNA5. J. Gen. Virol., 74: 1393-1398, 1993.
38. Burrows, P. D., Kearney, J. F., Schroeder, H. W., and Cooper, M. D. Normal B lymphocyte differentiation. Bailliere's Clin. Haematol., 6: 785-806, 1993.
39. Delmer, A., Ajchenbaum-Cymbalista, F., Tang, R., Ramond, S., Faussat, A., Marie, J., and Zittoun, D. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood, 85: 2870-2876, 1995.
40. Ehlin-Henriksson, B., Manneborg-Sandlung, A., and Klein, G. Expression of B-cell-specific markers in different Burkitt lymphoma subgroups. Int. J. Cancer, 39: 211-218, 1987.
41. Lenoir, G. M., Viullaume, M., and Bonardel, C. The Use of Lymphatous and Lymphoblastoid Cell Lines in the Study of Burkitt's Lymphoma. Burkitt's Lymphoma: A Human Cancer Model. IARC Sci. Publ., 60: 309-318, 1985.
42. Torsteinsdottir, S., Andersson, M., Avila-Carino, J., Ehlin-Henriksson, B., Masucci, M., Klein, G., and Klein, E. Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line. Int. J. Cancer, 43: 273-278, 1989.
43. Contreras-Salazar, B., Ehlin-Henriksson, B., Klein, G., and Masucci, M. G. Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection. J. Virol., 64: 5441-5447, 1990.
44. Kieff, E., and Liebowitz, D. Epstein-Barr virus and its replication. In: B. N. Fields and D. M. Knipe, Virology, pp. 1889-1920. New York: Raven Press, Ltd., 1990.
45. Contreras-Brodin, B., Anvret, M., Imreh, S., Altiok, E., Klein, G., and Masucci, M. B cell phenotype-dependent expression of the Epstein-Barr virus nuclear antigens EBNA-2 to EBNA-6: studies with somatic cell hybrids. J. Gen. Virol., 72: 3025-3033, 1991.
46. Cuomo, L., Trivedi, P., Wang, F., Winberg, G., Klein, G., and Masucci, M. Expression of the Epstein-Barr virus (EBV)-encoded membrane antigen (LMP) increases the stimulatory capacity of EBV-negative B lymphoma lines in allogenic mixed lymphocyte cultures. Eur. J. Immunol., 20: 2293-2299, 1990.
47. Finke, J., Rowe, M., Ernberg, I., Rosen, A., Dillner, J., and Klein, G. Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J. Virol., 61: 3870-3878, 1987.
48. Dooley, S., Ehrhart, E., Radtke, J., Unteregger, G., and Blin, N. A procedure for simultaneous isolation of undegraded RNA, DNA, and nuclear proteins suitable for interaction analysis in homologous systems. Methods Mol. Cell. Biol., 1: 95-105, 1989.
49. Williams, C. A., and Krawisz, B. R. Aurintricarboxylic acid as a ribonuclease inhibitor. Methods Mol. Cell. Biol., 1: 35-40, 1989.
50. Bartkova, J., Zemanova, M., and Bartek, J. Abundance and subcellular localisation of cyclin D3 in human tumors. Int. J. Cancer, 65: 323-327, 1996.
51. Reedman, B. M., and Klein, G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int. J. Cancer, 11: 499-520, 1973.
52. Szekely, L., Pokrovskaja, K., Jiang, W-Q., Selivanova, G., Löwbeer, M., Ringertz, N., Klein, G., and Wiman, K. G. Resting B-cells, EBV-infected B-blasts and established lymphoblastoid cell lines differ in their RB, p53 and EBNA-5 expression patterns. Oncogene, 10: 1869-1874, 1995.